Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mallinckrodt OxiFirst Fetal Oxygen Monitor To Be Sold By Specialized Reps

This article was originally published in The Gray Sheet

Executive Summary

Mallinckrodt is planning to sell its OxiFirst fetal oxygen saturation monitoring system through a dedicated sales force covering the entire U.S. FDA approval of the device was announced May 15.

You may also be interested in...



Nellcor OxiFirst Verdict Contingent On NIH FOX Trial Results, Panel Agrees

Upgraded software for Nellcor's OxiFirst N400 fetal pulse oximetry system will be included in NIH's Fetal Oximetry trial (FOX), as the company attempts to ward off adverse events associated with misuse of the device

Nellcor OxiFirst Verdict Contingent On NIH FOX Trial Results, Panel Agrees

Upgraded software for Nellcor's OxiFirst N400 fetal pulse oximetry system will be included in NIH's Fetal Oximetry trial (FOX), as the company attempts to ward off adverse events associated with misuse of the device

Mallinckrodt/NIH OxiFirst Fetal Oximetry Trial Will Evaluate Cesarean Rates

Results of an NIH-supported, postmarket study of Mallinckrodt's OxiFirst fetal oxygen saturation monitoring system, evaluating the associated cesarean section rate, are at least four years away, according to the National Institutes of Health.

Related Content

UsernamePublicRestriction

Register

MT013409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel